Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AR-17043
- Development stage
- Phase 2
- Lead developer
- Alcon
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
AR-17043 is a small molecule drug candidate being developed by Alcon for the treatment of open-angle glaucoma and ocular hypertension. It is administered as an ophthalmic solution (eye drops). The precise mechanism of action for AR-17043 has not been publicly defined, but it belongs to the antiglaucoma class. Clinical trials are ongoing, with Phase II studies evaluating its safety and efficacy in reducing intraocular pressure in patients with open-angle glaucoma or ocular hypertension[1][2][4]. Alcon is also developing a fixed-dose combination product (PG 043) that includes AR-17043 and latanoprost[5].
- Other names
- AR 17043AR17043AR-17043
02
Targets
PTGFR (Prostaglandin F2 alpha receptor)
Beyond the preview
Go deeper on AR-17043.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AR-17043.